Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor Size

Shinichiro Nakamura(Himeji Red Cross Hospital), Yasushi Shiratori(Beijing Red Cross Blood Center), Nobuyuki Toshikuni(Kansai Medical University), Yasuhiro Miyake(High Energy Accelerator Research Organization), Kohsaku Sakaguchi(Okayama University), Yoichi M. Ito(Hokkaido University), Yoshiyuki Kobayashi(Okayama University), Hironori Tanaka(Hyogo Medical University), Eiji Matsumoto(Nagoya University), Yasuo Ohashi(Chuo University), Kazuhiro Nouso(Okayama Prefecture)
The American Journal of Gastroenterology
July 18, 2006
10.1111/j.1572-0241.2006.00681.x
Cited by 165

Related Papers

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD)
|Circulation|2018|245